Abnova Taiwan Corp
TWSE:4133
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| TW |
|
Abnova Taiwan Corp
TWSE:4133
|
1.4B TWD |
Loading...
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
979.9B USD |
Loading...
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
175B USD |
Loading...
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
136B USD |
Loading...
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW |
Loading...
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
33B CHF |
Loading...
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
264.5B CNY |
Loading...
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
31.4B USD |
Loading...
|
|
| US |
|
Waters Corp
NYSE:WAT
|
28.9B USD |
Loading...
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
28.6B USD |
Loading...
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
24.2B USD |
Loading...
|
Market Distribution
| Min | -197.7% |
| 30th Percentile | 13.7% |
| Median | 22.1% |
| 70th Percentile | 31.4% |
| Max | 400.8% |
Other Profitability Ratios
Abnova Taiwan Corp
Glance View
Abnova Taiwan Corp. is engaged in researching, developing, manufacturing and selling antibodies. The company is headquartered in Taipei City, Taipei. The company went IPO on 2008-05-27. The firm's products mainly include monoclonal antibodies, polyclonal antibodies, protein fragments, full-length proteins, active proteins, antibody pairs, fluorescence in situ hybridization probe and others. The firm's monoclonal and polyclonal antibodies are primarily applied in medical testing reagents, agricultural testing, industrial purification, medical treatment and other fields. Its proteins are mainly applied in medical testing reagents, agricultural testing, medical treatment, protein engineering and other fields. Its products are mainly traded in Taiwan, Americas and Europe.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Abnova Taiwan Corp is 44.4%, which is below its 3-year median of 45.8%.
Over the last 3 years, Abnova Taiwan Corp’s Gross Margin has decreased from 48.9% to 44.4%. During this period, it reached a low of 43.4% on Sep 30, 2025 and a high of 48.9% on Dec 31, 2022.
